Li Ren

Prof. Li Ren

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Carbohydrate Polymers
Verified
Journal Article
Closed access
YYYang Yang
Yang Yang
HYHaiqing Ye
Haiqing Ye
Changhui ZhaoChanghui Zhao
Changhui Zhao
LRLi Ren
Li Ren
Cuina WangCuina Wang
Cuina Wang
TZTiehua Zhang
Tiehua Zhang

9 August 2018 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
QLQinglan Li
Qinglan Li
YSYao Sun
Yao Sun
LRLi Ren
Li Ren
XWXin Wang
Xin Wang
CWChen Wang
Chen Wang
JYJihong Yu
Jihong Yu

1 February 2016 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
LRLi Ren
Li Ren
ACAmanda Campbell
Amanda Campbell
HFHuiqing Fang
Huiqing Fang
SGShalini Gautam
Shalini Gautam
SESaranya Elavazhagan
Saranya Elavazhagan
STSusheela Tridandapani
Susheela Tridandapani
The irreversible Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown efficacy against B-cell tumors such as chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. Fcγ receptors (FcγR) on immune cells such as macrophages play an important role in tumor-specific antibody-mediated immune responses, but many such responses involve Btk. Here we tested the effects of ibrutinib on FcγR-mediated activities in monocytes. We found that ibrutinib did not affect monocyte FcγR-mediated phagocytosis, even at concentrations higher than those achieved physiologically, but suppressed FcγR-mediated cytokine production. We confirmed these findings in macrophages from Xid mice in which Btk signaling is defective. Because calcium flux is a major event downstream of Btk, we tested whether it was involved in phagocytosis. The results showed that blocking intracellular calcium flux decreased FcγR-mediated cytokine production but not phagocytosis. To verify this, we measured activation of the GTPase Rac, which is responsible for actin polymerization. Results showed that ibrutinib did not inhibit Rac activation, nor did the calcium chelator 1,2-bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis(acetoxymethyl ester). We next asked whether the effect of ibrutinib on monocyte FcγR-mediated cytokine production could be rescued by IFNγ priming because NK cells produce IFNγ in response to antibody therapy. Pretreatment of monocytes with IFNγ abrogated the effects of ibrutinib on FcγR-mediated cytokine production, suggesting that IFNγ priming could overcome this Btk inhibition. Furthermore, in monocyte-natural killer cell co-cultures, ibrutinib did not inhibit FcγR-mediated cytokine production despite doing so in single cultures. These results suggest that combining ibrutinib with monoclonal antibody therapy could enhance chronic lymphocytic leukemia cell killing without affecting macrophage effector function.

20 December 2017 in ACS Applied Materials & Interfaces
Verified
Journal Article
Closed access
QLQinglan Li
Qinglan Li
DWDuo Wang
Duo Wang
YCYuanzheng Cui
Yuanzheng Cui
ZFZhiying Fan
Zhiying Fan
LRLi Ren
Li Ren
JYJihong Yu
Jihong Yu

18 February 2022 in Phytomedicine
Verified
Journal Article
Closed access
PXPeiyu Xue
Peiyu Xue
GZGuangjie Zhang
Guangjie Zhang
Jie ZhangJie Zhang
Jie Zhang
LRLi Ren
Li Ren

1 March 2015 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
YZYiming Zhong
Yiming Zhong
SDShuai Dong
Shuai Dong
ESEthan Strattan
Ethan Strattan
LRLi Ren
Li Ren
JBJonathan P. Butchar
Jonathan P. Butchar
JDJason A. Dubovsky
Jason A. Dubovsky
Interleukin-2-inducible T-cell kinase (ITK) and resting lymphocyte kinase (RLK or TXK) are essential mediators of intracellular signaling in both normal and neoplastic T-cells and natural killer (NK) cells. Thus, ITK and RLK inhibitors have therapeutic potential in a number of human autoimmune, inflammatory, and malignant diseases. Here we describe a novel ITK/RLK inhibitor, PRN694, which covalently binds to cysteine residues 442 of ITK and 350 of RLK and blocks kinase activity. Molecular modeling was utilized to design molecules that interact with cysteine while binding to the ATP binding site in the kinase domain. PRN694 exhibits extended target residence time on ITK and RLK and is highly selective for a subset of the TEC kinase family. In vitro cellular assays confirm that PRN694 prevents T-cell receptor- and Fc receptor-induced cellular and molecular activation, inhibits T-cell receptor-induced T-cell proliferation, and blocks proinflammatory cytokine release as well as activation of Th17 cells. Ex vivo assays demonstrate inhibitory activity against T-cell prolymphocytic leukemia cells, and in vivo assays demonstrate durable pharmacodynamic effects on ITK, which reduces an oxazolone-induced delayed type hypersensitivity reaction. These data indicate that PRN694 is a highly selective and potent covalent inhibitor of ITK and RLK, and its extended target residence time enables durable attenuation of effector cells in vitro and in vivo. The results from this study highlight potential applications of this dual inhibitor for the treatment of T-cell- or NK cell-mediated inflammatory, autoimmune, and malignant diseases.